A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients

• Published in: Molecular cancer research 2022-02, Vol.20 (2), p.244-252
• Main Authors: Pauli, Chantal, De Boni, Lamberto, Pauwels, Jonathan E, Chen, Yanjiang, Planas-Paz, Lara, Shaw, Reid, Emerling, Brooke M, Grandori, Carla, Hopkins, Benjamin D, Rubin, Mark A
• Format: Article
• Language: English
• Subjects: Animals; Biomarkers, Tumor - metabolism; Female; Fibrosarcoma - physiopathology; High-Throughput Nucleotide Sequencing - methods; Humans; Medical Oncology - methods; Mice; Mice, Nude; Molecular Targeted Therapy - methods; Mutation; Precision Medicine - methods
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.mcr-21-0255

In this era of precision medicine, numerous workflows for the targeting of high-recurrent mutations in common tumor types have been developed, leaving patients with rare diseases with few options. Here, we implement a functional precision oncology approach utilizing comprehensive genomic profiling in combination with high-throughput drug screening, to identify tumor-specific drug sensitivities for patients with rare tumor types such as myxofibrosarcoma. From a patient with a high-grade myxofibrosarcoma, who was enrolled in the Englander Institute for Precision Medicine (EIPM) program, we established patient-derived 3D - and models for functional testing. In the absence of a large cohort of clinically similar cases, high-throughput drug screening was performed on the patient-derived cells, and compared with two other myxofibrosarcoma lines and a benign fibroblast line to functionally identify tumor-specific drug sensitivities. The addition of functional drug sensitivity testing to complement genomic profiling identified multiple therapeutic options that were further validated in patient derived xenograft models. Genomic analyses detected the frequently known codeletion of the tumor suppressors together with the methylthioadenosine phosphorylase ( ) and a E286fs*50 mutation. High-throughput drug screening demonstrated tumor-specific sensitivity to compounds targeting the cell cycle. Based on genomic analysis and high-throughput drug screening, we show that targeting the cell cycle in these tumors is a powerful approach. IMPLICATIONS: This study demonstrates the potential of functional testing to aid clinical decision making for patients with rare or molecularly complex malignancies when combined with comprehensive genomic profiling.